Acitretin
- Generic Name
- Acitretin
- Brand Names
- Soriatane
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O3
- CAS Number
- 55079-83-9
- Unique Ingredient Identifier
- LCH760E9T7
- Background
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
- Indication
For the treatment of severe psoriasis in adults.
- Associated Conditions
- Keratinization disorders, Severe Psoriasis
Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT02191020
- Locations
- 🇨🇳
Xijing Hospitial, Xi'an, Shaanxi, China
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
- Conditions
- Psoriasis, Skin or Nails
- Interventions
- Device: Excimer laser
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 2
- Registration Number
- NCT02181790
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 2
- Registration Number
- NCT02050321
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
- Conditions
- Psoriasis
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Jochen Schmitt.
- Target Recruit Count
- 1
- Registration Number
- NCT01812954
Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01545284
- Locations
- 🇨🇦
Windsor Clinical Research Inc., Windsor, Ontario, Canada
🇨🇦Innovaderm Research Inc., Montreal, Quebec, Canada
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2011-09-29
- Lead Sponsor
- Ministry of Health, China
- Target Recruit Count
- 720
- Registration Number
- NCT01443338
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
- Conditions
- Skin Rash
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT01299220
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2011-06-22
- Lead Sponsor
- Frankel, Amylynne, M.D.
- Target Recruit Count
- 20
- Registration Number
- NCT01228409
- Locations
- 🇺🇸
Mount Sinai Clinical Trials, New York, New York, United States
Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
- Conditions
- Psoriasis
- Interventions
- Device: Excimer laserDevice: Sham excimer laser
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 13
- Registration Number
- NCT01094717
- Locations
- 🇺🇸
University of Utah Department of Dermatology, Salt Lake City, Utah, United States
Alzheimer's Disease Acitretin Medication
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- K. Lieb
- Target Recruit Count
- 22
- Registration Number
- NCT01078168
- Locations
- 🇩🇪
Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz, Mainz, Rheinland-Pfalz, Germany
🇩🇪Universität Rostock, Rostock, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.